Press Releases
Site - Investor Relations
Predictive Oncology Inc. to Attend BIO DIGITAL, the World’s Largest Biotech Partnering Experience
The three
“Our Helomics division is leveraging the BIO one-on-one partnering™ sessions to actively pursue strategic opportunities and partnerships, demonstrating where our PeDAL™ platform (Patient-centric Drug Discovery using Active Learning) can be applied for precision medicine discovery. Our unique approach allows Pharma therapeutic groups to see how we embrace the complexity and diversity of patient tumors in a highly-scalable and efficient experimental exploration of drugs and drug combinations for patient-specific populations,” said
“We are also looking forward to sharing the capabilities of our Soluble Biotech division,” Engle stated. In previous conferences Soluble Biotech has typically received more than a dozen requests for proposals, leading to new contracts for their main service of providing protein therapeutic formulations (i.e., formulations for vaccines, antibodies, virus-like particles). Soluble Biotech uses a proprietary technology, a high-throughput self-interaction chromatography (HSC), that enables cost effective formulation development in just four months using 1/10 the sample amount required by its competitors.
“Our TumorGenesis division is focused on offering products and services for culturing cancer cells from ovarian and breast cancers that mimic the patient’s tumors more accurately. The TumorGenesis media used in ovarian cancer samples holds DNA/RNA and proteomic signatures to 95% of what the original tumor was expressing, while retaining the morphology structure that develops as the samples grow. This allows us to fool cancer cells, with our media giving the cells what they want to grow ex-vivo, just like they will need to grow in vivo. We are excited to see the interest in our specialty media from both Biotech and Pharm companies,” said Engle.
About
Forward-Looking Statements
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements because of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the
Investor Relations Contact:
(404) 995-6671
kpinder@landoncapital.net
Source: Predictive Oncology Inc.